Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin

Human Immunology

Volumn 71, Issue 10, 2010, Pages 957-963

  Subbramanian, Ramu A ^a   Basha, Saleem ^a   Brady, Rebecca C ^a   Hazenfeld, Staci ^a   Shata, Mohamed T ^b   Bernstein, David I ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antigenic domains; Cellular immunity; ELISPOT; Influenza virus; Vaccine

Indexed keywords

GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ;

ADULT; AGE; ANTIGENIC DRIFT; ANTIGENIC VARIATION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA VIRUS A H1N1; MEMBRANE FUSION; NORMAL HUMAN; PANDEMIC; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA;

ADOLESCENT; ADULT; AGE FACTORS; ANTIGENIC VARIATION; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; MIDDLE AGED; PANDEMICS; UNITED STATES;

EID: 77956616226     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.07.005     Document Type: Article

References (38)

1. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(Suppl 1):S3-S10.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
4. CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States February 13 2010, April 2009 CDC. http://cdcgov/h1n1flu/estimates_2009_h1n1htm.
5. Palese P. Influenza: Old and new threats. Nat Med 2004, 10:S82-S87.
6. Lin Y.P., Gregory V., Bennett M., Hay A. Recent changes among human influenza viruses. Virus Res 2004, 103:47-52.
7. Update: Influenza activity-United States and worldwide, 2006-07 season, and composition of the 2007-08 influenza vaccine. MMWR. Morb Mortal Wkly Rep 2007, 56:789-794.
8. Update: Influenza activity-United States October 1, 2006-February 3, 2007. MMWR Morb Mortal Wkly Rep 2007, 56:118-121.
9. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
10. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
11. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: A cross-sectional serological study. Lancet 2010, 375:1100-1108.
12. Chen H., Wang Y., Liu W., Zhang J., Dong B., Fan X., et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis 2009, 15:1849-1850.
13. Mozdzanowska K., Furchner M., Maiese K., Gerhard W. CD4+ T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 1997, 239:217-225.
14. + T cells is inefficient in the absence of B cells. J Virol 1998, 72:882-885.
15. McElhaney J.E., Xie D., Hager W.D., Barry M.B., Wang Y., Kleppinger A., et al. T-cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006, 176:6333-6339.
16. Patel A., Tran K., Gray M., Li Y., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27:3083-3089. Z.
17. Kiecker F., Streitz M., Ay B., Cherepnev G., Volk H.D., Volkmer-Engert R., Kern F. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose?. Hum Immunol 2004, 65:523-536.
18. Shata M.T., Barrett A., Shire N.J., Abdelwahab S.F., Sobhy M., Daef E., et al. Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay. J Immunol Methods 2007, 328:152-161.
19. Anthony D.D., Lehmann P.V. T-cell epitope mapping using the ELISPOT approach. Methods San Diego Calif 2003, 29:260-269.
20. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31:417-427.
21. Raymond F.L., Caton A.J., Cox N.J., Kendal A.P., Brownlee G.G. The antigenicity and evolution of influenza H1 haemagglutinin, from 1950-1957 and 1977-83: Two pathways from one gene. Virology 1986, 148:275-287.
22. Fanning T.G., Taubenberger J.K. Phylogenetically important regions of the influenza A H1 hemagglutinin protein. Virus Res 1999, 65:33-42.
23. Gerhard W., Yewdell J., Frankel M.E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981, 290:713-717.
24. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289:373-378.
25. Wilson I.A., Cox N.J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Review Immunol 1990, 8:737-771.
26. Both G.W., Sleigh M.J., Cox N.J., Kendal A.P. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: Multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 1983, 48:52-60.
27. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58:195-207.
28. Treanor J., Wright P.F. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003, 115:97-104.
29. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., Abrutyn E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
30. Renegar K.B. Influenza virus infections and immunity: A review of human and animal models. Lab Anim Sci 1992, 42:222-232.
31. Davies J.R., Grilli E.A. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses. Epidemiol Infect 1989, 102:325-333.
32. Reinhardt R.L., Liang H.E., Locksley R.M. Cytokine-secreting follicular T cells shape the antibody repertoire. Nat Immunol 2009, 10:385-393.
33. Zheng J., Liu Y., Lau Y.L., Tu W. CD40-activated B cells are more potent than immature dendritic cells to induce and expand;CD4(+) regulatory T cells. Cell Mol Immunol 2010, 7:44-50.
34. Brydak L.B., Tadeusz S., Magdalena M. Antibody response to influenza vaccination in healthy adults. Viral Immunol 2004, 17:609-615.
35. Barry D.W., Mayner R.E., Staton E., Dunlap R.C., Rastogi S.C., Hannah J.E., et al. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man. Am J Epidemiol 1976, 104:34-46.
36. Ge X., Tan V., Bollyky P.L., Standifer N.E., James E.A., Kwok W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010, 84:3312-3319.
37. Tu W., Mao H., Zheng J., Liu Y., Chiu S.S., Qin G., et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010, 84:6527-6535.
38. Katz J.M., Plowden J., Renshaw-Hoelscher M., Lu X., Tumpey T.M., Sambhara S. Immunity to influenza: The challenges of protecting an aging population. Immunol Res 2004, 29:113-124.